Company Reports / Abbott Laboratories

COMPANY: Abbott Laboratories


Total Impact Score: 85,896.66

Abbott Laboratories is ranked 12th place in our index for 2015. Abbott Laboratories’s drugs have a total impact score of 85,896.66. Abbot Laboratories treats one disease in our model - HIV - with one total drug - Lopinavir / Ritonavir (LPV/r). Abbot Laboratories receives credit for one treatment against HIV - Lopinavir / Ritonavir (LPV/r). This one drug averted 83,658.48 of the total DALYS for HIV, which is 3.26% of the worldwide DALYs that we estimate would have been lost due to HIV in 2015 in the absence of effective treatment. Abbot Laboratories’s drug portfolio placed it 6th in terms of total averted DALYs for HIV

Company Score Breakdown:

Key Drugs


Lopinavir/ritonavir (LPV/r) is an ARV combination drug recommended by the WHO in the treatment of HIV as a part of preferred second-line regimen for adults, adolescents, and children older than three years, as a part of the preferred first-line regimen for children under three years old, and recommended in cases with HBV coinfection. Major toxicity concerns include hepatotoxicity, pancreatitis and electrocardiographic abnormalities. It was patented by Abbott Laboratories in 1996.

Company Information

Abbott Laboratories is a global pharmaceutical company headquartered in Illinois and founded by Dr. Wallace C. Abbott in 1888. Their products emphasize pain management, cardiovascular disease, nutrition, diabetes care, diagnostics and emerging-market pharmaceuticals. Their products for pancreatic enzyme replacement therapy (Creon), progesterone deficiency (Duphaston), and anti-vertigo medicine (Serc), lead in key emerging markets. In 1985, Abbott developed the world’s first HIV blood-screen test. Currently, Abbot is the largest manufacturer of HIV rapid tests, priding itself on its focus on point-of-care testing in the fight against HIV. In 2017, they delivered more than one billion healthcare professionals and patients worldwide. Other significant products include Similac and Pediasure. Abbott currently has over 99,000 employees across 150 countries, and their revenue in 2017 exceeded $27.3 billion.

Company Report PDF